Cargando…

Hepatitis B virus surface antigen seroconversion in HIV-infected individual after pegylated interferon-alpha treatment: a case report

Hepatitis B virus (HBV) infects from 6 to 14% of HIV-infected individuals. Concurrent HIV/HBV infection occurs due to the overlapping routes of transmission, particularly sexual and parenteral. HIV-infected patients that have acute hepatitis B have six times greater risk of developing chronic hepati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Delicio, Adriane Maira, Abati, Paulo Afonso Martins, Vigani, Aline Gonzalez
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029789/ https://www.ncbi.nlm.nih.gov/pubmed/24325818 http://dx.doi.org/10.1186/1678-9199-19-31

Ejemplares similares

Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B
por: Zhang, Wenhong, et al.
Publicado: (2018)

Pegylated Interferon Alpha for Chronic Hepatitis B Virus Infection
por: Vasconcelos, Joana, et al.
Publicado: (2022)

Factors Associated with Hepatitis B Surface Antigen Kinetics and Responses in Pegylated Interferon Alpha-2a Monotherapy for Patients with Chronic Hepatitis B
por: Itokawa, Norio, et al.
Publicado: (2021)

Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment
por: Li, Ming-Hui, et al.
Publicado: (2017)

Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin
por: Carvalho-Filho, Roberto J, et al.
Publicado: (2010)

Pegylated interferon-alpha-2a for the treatment of ocular surface squamous neoplasia
por: Nuruddin, Murtuza, et al.
Publicado: (2022)

Pegylated-Interferon Alpha Therapy for Treatment-Experienced Chronic Hepatitis B Patients
por: Yeh, Ming-Lun, et al.
Publicado: (2015)

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
por: Gonçales, Fernando L, et al.
Publicado: (2010)

Nanomedicines in the treatment of chronic hepatitis C – focus on pegylated interferon alpha-2a
por: Thomas, Thea, et al.
Publicado: (2007)

Seroconversion of Hepatitis B Virus Surface Antigen in Chronic Hepatitis B Child Treated with Entecavir
por: Li, Dong, et al.
Publicado: (2012)

‘Double-hit’ pegylated interferon-alpha successfully treats Hepatitis B and Hepatitis D co-infection
por: Bhuva, Meha, et al.
Publicado: (2020)

Analysis of the Efficacy and Safety of PEGylated Interferon-α2b Treatment in Inactive Hepatitis B Surface Antigen Carriers
por: Huang, Yan, et al.
Publicado: (2021)

HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b
por: Ma, Hui, et al.
Publicado: (2016)

Using machine learning models to predict HBeAg seroconversion in CHB patients receiving pegylated interferon‐α monotherapy
por: Shang, Hongyan, et al.
Publicado: (2022)

Hepatitis B surface antigen and hepatitis B core-related antigen kinetics after adding pegylated-interferon to nucleos(t)ids analogues in hepatitis B e antigen-negative patients
por: Broquetas, Teresa, et al.
Publicado: (2020)

Pegylated interferon alpha-2a (40 kDa) in the treatment of chronic hepatitis B
por: Lai, Lawrence, et al.
Publicado: (2006)

Nanomedicines in the treatment of patients with hepatitis C co-infected with HIV – focus on pegylated interferon-alpha
por: Zoller, Heinz, et al.
Publicado: (2006)

Acute pericarditis due to pegylated interferon alpha therapy for chronic HCV hepatitis - Case report
por: Popescu, Cristina, et al.
Publicado: (2011)

Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C
por: Choi, Jong Wook, et al.
Publicado: (2016)

Thyroid disturbances in children treated with combined pegylated interferon-alpha and ribavirin for chronic hepatitis C
por: Rashed, Yasser K., et al.
Publicado: (2020)

Pegylated interferon/telbivudine sequential therapy in Hepatitis Be antigen negative severe chronic hepatitis B patient
por: Caroleo, Benedetto, et al.
Publicado: (2013)

Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B
por: Liem, Kin Seng, et al.
Publicado: (2019)

Pegylated Interferon Treatment for the Effective Clearance of Hepatitis B Surface Antigen in Inactive HBsAg Carriers: A Meta-Analysis
por: Song, Aixin, et al.
Publicado: (2021)

Differential expression of interferon-induced microRNAs in patients with chronic hepatitis C virus infection treated with pegylated interferon alpha
por: Scagnolari, Carolina, et al.
Publicado: (2010)

Large Intestine Histopathology of Pegylated-Interferon-Alpha Plus Ribavirin Treated Chronic Hepatitis C Patients
por: Pantazis, Konstantinos D., et al.
Publicado: (2008)

Pegylated interferon alpha-2a monotherapy in a peritoneal dialysis patient with chronic hepatitis C
por: Mimura, Imari, et al.
Publicado: (2008)

Comparison of adefovir dipivoxil and pegylated interferon alpha-2a treatment in chronic hepatitis B patients
por: Korkmaz, Pinar, et al.
Publicado: (2014)

Ischaemic colitis during pegylated interferon-alpha monotherapy for chronic hepatitis B: A case report
por: Liu, Yu, et al.
Publicado: (2022)

Analysis of clinical characteristics of thyroid disorders in patients with chronic hepatitis B treated with pegylated-interferon alpha
por: Liu, Yisi, et al.
Publicado: (2023)

Interleukin‐2 promotes pegylated interferon alpha for hepatitis B surface antigen loss: A retrospective pragmatic clinical study at the Fourth Affiliated Hospital of Zhejiang University Medical College
por: Qi, Wencai, et al.
Publicado: (2022)

Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis
por: Huang, Yi-Wen, et al.
Publicado: (2022)

The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C
por: Keshvari, Maryam, et al.
Publicado: (2016)

Seroconversion of hepatitis B surface antigen among those with previously successful immune response in Southern China
por: Zheng, Zhigang, et al.
Publicado: (2020)

Hepatitis C Virus Clearance after Discontinuation of Pegylated Interferon Alpha-2a Monotherapy in a Child
por: Endo, Takeshi, et al.
Publicado: (2012)

Add-on Pegylated Interferon Alpha-2a Therapy in Chronic Hepatitis B Japanese Patients Treated with Entecavir
por: Tamai, Hideyuki, et al.
Publicado: (2017)

Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B
por: Zheng, Caixia, et al.
Publicado: (2019)

Non-pegylated and Pegylated Interferon Alpha-2a in Cutaneous T-cell Lymphoma and the Risk of Severe Ocular Side-effects
por: ALBRECHT, Jana D., et al.
Publicado: (2022)

Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection
por: Kagawa, Tatehiro, et al.
Publicado: (2010)

Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea
por: Cho, Hyun Chin, et al.
Publicado: (2013)

Pegylated Interferons: Clinical Applications in the Management of Hepatitis C Infection
por: Matthews, S. James, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_elrn88emivbt1peodbrgh3d8q9